Last November, Nuritas, the Irish biotechnology company, closed a massive $45 million funding round to help accelerate its global expansion. The round brought the company’s total funding to $75 million and was a statement of confidence from a host of big-name backers including Chicago-based Cleveland Avenue, Grosvenor’s Wheatsheaf Group, and the European Circular Bioeconomy Fund (ECBF). Existing investors such as Bono, Adam Clayton and The Edge as well as Cultivian Sandbox Ventures also participated. The capital injection has shored up the company’s financial position, as evidenced by accounts filed by Nuritas in recent days for the 2021 financial year. When…

Want to continue reading?

Introductory offer: Sign up today and pay €200 for an annual membership, a saving of €100.

Subscribe

Cancel anytime.

Are you already a member? .